Cargando…

Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death worldwide, because recurrence often occurs in most HCC patients undergoing hepatectomy. It is necessary to identify patients with high risk for recurrence and adopt effective therapies. An obstacle to monitor patients at hig...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Binghua, Feng, Wendu, Luo, Ouyang, Xu, Tiancheng, Cao, Yajuan, Wu, Hongyan, Yu, Decai, Ding, Yitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514049/
https://www.ncbi.nlm.nih.gov/pubmed/28717245
http://dx.doi.org/10.1038/s41598-017-04811-5
_version_ 1783250766895513600
author Li, Binghua
Feng, Wendu
Luo, Ouyang
Xu, Tiancheng
Cao, Yajuan
Wu, Hongyan
Yu, Decai
Ding, Yitao
author_facet Li, Binghua
Feng, Wendu
Luo, Ouyang
Xu, Tiancheng
Cao, Yajuan
Wu, Hongyan
Yu, Decai
Ding, Yitao
author_sort Li, Binghua
collection PubMed
description Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death worldwide, because recurrence often occurs in most HCC patients undergoing hepatectomy. It is necessary to identify patients with high risk for recurrence and adopt effective therapies. An obstacle to monitor patients at high risk for poor prognosis has been the lack of useful predictive biomarkers. Fortunately, recent progress in system biology allows to screen the biomarkers for HCC prognosis in a high-throughput manner. In this study, we performed systematic Kaplan-Meier survival analysis of the whole mRNA transcriptomics based on the Cancer Genome Atlas project (TCGA) and developed a three-gene prognostic signature composing of three genes UPB1, SOCS2 and RTN3. The model was validated in two independent microarray data sets retrieved from Gene Expression Omnibus (GEO) and the expression pattern of these three predictive genes in HCC was confirmed by western blot and immunohistochemistry with our HCC samples. In conclusion, our results showed that this three-gene signature has prognostic value for HCC patients.
format Online
Article
Text
id pubmed-5514049
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-55140492017-07-19 Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma Li, Binghua Feng, Wendu Luo, Ouyang Xu, Tiancheng Cao, Yajuan Wu, Hongyan Yu, Decai Ding, Yitao Sci Rep Article Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death worldwide, because recurrence often occurs in most HCC patients undergoing hepatectomy. It is necessary to identify patients with high risk for recurrence and adopt effective therapies. An obstacle to monitor patients at high risk for poor prognosis has been the lack of useful predictive biomarkers. Fortunately, recent progress in system biology allows to screen the biomarkers for HCC prognosis in a high-throughput manner. In this study, we performed systematic Kaplan-Meier survival analysis of the whole mRNA transcriptomics based on the Cancer Genome Atlas project (TCGA) and developed a three-gene prognostic signature composing of three genes UPB1, SOCS2 and RTN3. The model was validated in two independent microarray data sets retrieved from Gene Expression Omnibus (GEO) and the expression pattern of these three predictive genes in HCC was confirmed by western blot and immunohistochemistry with our HCC samples. In conclusion, our results showed that this three-gene signature has prognostic value for HCC patients. Nature Publishing Group UK 2017-07-17 /pmc/articles/PMC5514049/ /pubmed/28717245 http://dx.doi.org/10.1038/s41598-017-04811-5 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Li, Binghua
Feng, Wendu
Luo, Ouyang
Xu, Tiancheng
Cao, Yajuan
Wu, Hongyan
Yu, Decai
Ding, Yitao
Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma
title Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma
title_full Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma
title_fullStr Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma
title_full_unstemmed Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma
title_short Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma
title_sort development and validation of a three-gene prognostic signature for patients with hepatocellular carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514049/
https://www.ncbi.nlm.nih.gov/pubmed/28717245
http://dx.doi.org/10.1038/s41598-017-04811-5
work_keys_str_mv AT libinghua developmentandvalidationofathreegeneprognosticsignatureforpatientswithhepatocellularcarcinoma
AT fengwendu developmentandvalidationofathreegeneprognosticsignatureforpatientswithhepatocellularcarcinoma
AT luoouyang developmentandvalidationofathreegeneprognosticsignatureforpatientswithhepatocellularcarcinoma
AT xutiancheng developmentandvalidationofathreegeneprognosticsignatureforpatientswithhepatocellularcarcinoma
AT caoyajuan developmentandvalidationofathreegeneprognosticsignatureforpatientswithhepatocellularcarcinoma
AT wuhongyan developmentandvalidationofathreegeneprognosticsignatureforpatientswithhepatocellularcarcinoma
AT yudecai developmentandvalidationofathreegeneprognosticsignatureforpatientswithhepatocellularcarcinoma
AT dingyitao developmentandvalidationofathreegeneprognosticsignatureforpatientswithhepatocellularcarcinoma